Amedisys Board of Directors Authorizes $100 million Stock Repurchase Program

Rhea-AI Summary

Amedisys, Inc. (NASDAQ: AMED) has authorized a stock repurchase program allowing the company to buy back up to $100 million of its common stock by December 31, 2021. CFO Scott Ginn noted the decision reflects the company's strong cash flow and low leverage, emphasizing that share buybacks will be part of their capital deployment strategy, alongside priority on acquisitions in Home Health and Hospice. Repurchases may occur through various methods, depending on market conditions and legal requirements.

Positive

• Authorization of a $100 million stock repurchase program, indicating confidence in the company's financial position.
• Strong cash flow and low leverage enable prudent share buybacks.
• Commitment to capital deployment strategy that includes both stock repurchases and accretive acquisitions.

Negative

• None.

BATON ROUGE, La., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), America’s leading independent home health, hospice and personal care company, today announced that its Board of Directors has authorized a stock repurchase program, under which the Company may repurchase up to $100 million of its outstanding common stock through December 31, 2021.

Scott Ginn, Chief Financial Officer, stated, “Given our strong cashflow and low leverage, we feel it is prudent to have authorization to buy-back shares throughout the course of the year, including shares granted under the Company’s Omnibus Incentive Plan as they vest in 2021. This will become a recurring part of our capital deployment strategy; however, our first priority is and will continue to be accretive acquisitions in both Home Health and Hospice.”

Under the stock repurchase program, the Company may repurchase its common stock from time to time, in amounts, at prices, and at such times as the Company deems appropriate, subject to market conditions and other considerations and in accordance with applicable federal securities laws and other legal requirements. The Company's repurchases may be executed using open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a 10b5-1 trading plan.

About Amedisys:
Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,600 hospitals and 67,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, Tenn., Amedisys is a publicly held company. With 21,000 employees in 516 care centers within 39 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 415,000 patients and clients in need every year. For more information about the Company, please visit: www.amedisys.com.

Forward-Looking Statements:
When included in this press release, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “would,” “should,” “will” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic (“COVID-19”), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, widespread protest or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

Contact:
Amedisys, Inc.
Investor Relations
855.259.2046
IR@amedisys.com

 

FAQ

What is the purpose of Amedisys' stock repurchase program?

The program aims to enhance shareholder value by utilizing the company's strong cash flow for repurchasing shares, which could positively impact the stock price.

How much common stock can Amedisys repurchase?

Amedisys can repurchase up to $100 million of its outstanding common stock through December 31, 2021.

What methods will Amedisys use for the stock buyback?

Repurchases may occur through open market purchases, privately negotiated transactions, accelerated stock repurchase programs, and 10b5-1 trading plans.

How does the stock repurchase impact Amedisys' acquisitions?

While stock buybacks are part of Amedisys' capital strategy, the company maintains that its first priority is still on making accretive acquisitions in Home Health and Hospice.